Endothelium-derived bone morphogenic protein antagonists may counteract the proatherogenic vascular effects of bone morphogenic protein 4.
Endothelium-derived bone morphogenic protein antagonists may counteract the proatherogenic vascular effects of bone morphogenic protein 4. Circulation. 2007 Sep 11; 116(11):1221-3.